💊 Arzneimittel A-Z 🧬 Targets 🛠 Werkzeuge 📚 Leitfäden
Alle Arzneimittel Arzneimittelklassen Therapeutische Bereiche Nebenwirkungen
Leitfäden Glossar Zeitleiste
Vergleiche Arzneimittelreisen Arzneimittel-Wirkstoffgruppen
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Pembrolizumab

CHEMBL3137343 Phase 4 Zugelassen Antibody
Half-Life
26 days
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

This immunotherapy helps the immune system recognize and attack cancer cells by blocking the PD-1 protein.

Therapeutische Bereiche

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Endometriosis Benign Prostatic Hyperplasia Glaucoma Cardiovascular Disease Age-Related Macular Degeneration Neurology Psychiatry Endocrinology Respiratory Disease Dermatology Hematology Pain Management Ophthalmology Non-Small Cell Lung Cancer Rheumatoid Arthritis Osteoporosis Asthma Chronic Obstructive Pulmonary Disease Immunology Alzheimer's Disease Parkinson's Disease Epilepsy Migraine Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Insomnia Infectious Disease Melanoma Hepatology Oncology Nephrology Gastroesophageal Reflux Disease Inflammatory Bowel Disease Psoriasis Obstetrics & Gynecology Anesthesiology Systemic Lupus Erythematosus Multiple Sclerosis Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Urology Stroke Deep Vein Thrombosis / Pulmonary Embolism Hyperlipidemia Obesity Lymphoma Gastroenterology Rheumatology Transplant Medicine Type 2 Diabetes Hypertension Major Depressive Disorder Breast Cancer Atopic Dermatitis Gout Chronic Pain Malaria HIV/AIDS Hepatitis C Tuberculosis Heart Failure Atrial Fibrillation Prostate Cancer Colorectal Cancer Leukemia

Arzneimittelklassen

L — L - Antineoplastic and Immunomodulating Agents

Wirkmechanismus

Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.

Pharmacokinetics (PK)

Half-Life 26 days

Pharmacodynamics (PD)

Mechanismus

Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.

HBD / HBA

- / -

PDCD1 (Programmed Cell Death Protein 1) Antagonist
Primary Target
CTLA4 (Cytotoxic T-Lymphocyte Antigen 4) Other
Moderate Pembrolizumab + Prednisone

Prednisone at immunosuppressive doses may blunt pembrolizumab's anti-tumour efficacy by dampening the T-cell responses required for checkpoint inhibitor activity.
Moderate Pembrolizumab + Dexamethasone

Systemic corticosteroids such as dexamethasone can attenuate pembrolizumab's immune-stimulating anti-tumour activity by suppressing the immune effector responses that the checkpoint inhibitor relies on.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

This immunotherapy helps the immune system recognize and attack cancer cells by blocking the PD-1 protein.

Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.

Key pharmacokinetic parameters for Pembrolizumab: Half-life: 26 days.

Yes, Pembrolizumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

ADME Journey →

Related Drugs

Same Drug Class

Methotrexate Small molecule Tamoxifen Small molecule Cyclosporine Protein Tacrolimus Small molecule
{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3137343. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.